AstraZeneca Hits And Misses: Trio Of EU Label Expansions But US Lynparza Review Delayed

 
• By Ayisha Sharma

The major has won two positive CHMP opinions and one EU approval for meaningful label expansions across its oncology and cardiology franchises, but a delayed US review for prostate cancer drug Lynparza has put a spanner in the works.  

Red rollercoaster against blue sky background
While Positive EU Opinions Abound, Things Are Looking Down In The US • Source: Shutterstock

More from Business

More from Scrip